JW (Cayman) Therapeutics Co. Ltd
JWCTF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $158 | $174 | $146 | $31 |
| % Growth | -9% | 19.3% | 373.1% | – |
| Cost of Goods Sold | $81 | $86 | $87 | $22 |
| Gross Profit | $77 | $88 | $59 | $9 |
| % Margin | 48.9% | 50.7% | 40.3% | 29.4% |
| R&D Expenses | $283 | $414 | $408 | $414 |
| G&A Expenses | $45 | $65 | $180 | $202 |
| SG&A Expenses | $145 | $118 | $371 | $372 |
| Sales & Mktg Exp. | $101 | $53 | $191 | $171 |
| Other Operating Expenses | $108 | $346 | $136 | -$19 |
| Operating Expenses | $537 | $878 | $915 | $768 |
| Operating Income | -$459 | -$790 | -$856 | -$759 |
| % Margin | -290.3% | -454.2% | -587.4% | -2,464.8% |
| Other Income/Exp. Net | -$131 | $22 | $10 | $57 |
| Pre-Tax Income | -$591 | -$768 | -$846 | -$702 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$591 | -$768 | -$846 | -$702 |
| % Margin | -373.3% | -441.7% | -580.7% | -2,280.5% |
| EPS | -1.43 | -1.87 | -2.06 | -1.76 |
| % Growth | 23.5% | 9.2% | -17% | – |
| EPS Diluted | -1.43 | -1.87 | -2.06 | -1.76 |
| Weighted Avg Shares Out | 414 | 412 | 410 | 400 |
| Weighted Avg Shares Out Dil | 414 | 412 | 410 | 400 |
| Supplemental Information | – | – | – | – |
| Interest Income | $28 | $34 | $17 | $8 |
| Interest Expense | $12 | $12 | $7 | $3 |
| Depreciation & Amortization | $90 | $100 | $87 | $33 |
| EBITDA | -$489 | -$656 | -$752 | -$739 |
| % Margin | -308.9% | -377.2% | -516.3% | -2,398.6% |